Instituto Rosenbusch's Total Assets for the quarter that ended in Dec. 2025 was ARS7,745 Mil.
During the past 12 months, Instituto Rosenbusch's average Total Assets Growth Rate was -19.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 22.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 46.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 48.40% per year.
During the past 13 years, Instituto Rosenbusch's highest 3-Year average Total Assets Growth Rate was 86.80%. The lowest was 7.40%. And the median was 21.40%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Instituto Rosenbusch's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Instituto Rosenbusch Total Assets Related Terms
Instituto Rosenbusch Total Assets Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Instituto Rosenbusch's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a Total Assets of ARS7,745 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Total Assets too high?
Instituto Rosenbusch's current Total Assets is ARS7,745 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Total Assets compare to ZTS and UTHR?
Instituto Rosenbusch's Total Assets of ARS7,745 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Total Assets is ARS7,745 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.07, compared to a current price of ARS160.00 — trading 157.8% above its estimated fair value. The current Total Assets is ARS7,745 Mil. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Total Assets is ARS7,745 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS160.00 is trading 157.8% above its estimated GF Value™ of ARS62.07.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Total Assets: ARS7,745 Mil
GF Value™: ARS62.07 vs. price of ARS160.00 (157.8% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score
Get the complete analysis for BUE:ROSE
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
